Open AccessVogt‐Koyanagi‐Harada disease‐like posterior uveitis in the course of nivolumab (anti‐PD‐1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma
Author(s) -
Matsuo Toshihiko,
Yamasaki Osamu
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.911
Subject(s) - medicine , vemurafenib , nivolumab , melanoma , vogt–koyanagi–harada disease , metastatic melanoma , antibody , dermatology , uveitis , immunology , immunotherapy , cancer research , immune system
Key Clinical Message A patient with metastatic cutaneous malignant melanoma developed Vogt‐Koyanagi‐Harada disease‐like posterior uveitis after two nivolumab (anti‐PD‐1 antibody) injections. Vogt‐Koyanagi‐Harada disease, with the background of autoimmunity against choroidal melanocytes, suggests nivolumab be working by disintegrating inhibition circuit of T cells against a common epitope shared between melanoma cells and normal melanocytes.